GlobeNewswire by notified

Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million

Share

23 January 2023

Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million

The deal includes a £41.7 million milestone payment and double-digit Proleukin® global sales royalties

Clinigen Limited (‘Clinigen’) (‘the Company’), the global pharmaceutical services company, has entered into an agreement to divest Proleukin® (interleukin-2 (aldesleukin)), to Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (‘Iovance’), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte (TIL) and peripheral-blood lymphocyte (PBL)).

Terms of the agreement include an upfront payment of £166.7 million, a £41.7 million milestone payment upon first approval of lifileucel in advanced melanoma, and double-digit Proleukin® global sales royalties from Iovance to Clinigen. The transaction is expected to close in the first quarter of 2023, subject to required regulatory approvals and clearances and other customary closing conditions.

The divestment of Proleukin is an important step in Clinigen’s previously stated strategy of increasing its focus on those areas of the pharmaceutical services market where it has a growing and sustainable competitive advantage. Clinigen provides a strong and highly differentiated offering in pharmaceutical services where the platform provides market-leading access solutions from the clinical phase through to the commercial stage of the drug product life cycle.

David Bryant, Interim Chief Executive Officer of Clinigen, said: “Today’s announcement is a significant milestone for Clinigen as it continues its evolution as a business focused on critical high-value pharmaceutical services. The divestment helps accelerate that services focus, while returning value to the business and allowing Clinigen to benefit from potential future economic value in Proleukin.

“We have had a long-standing partnership with Iovance and believe they are the right partner to take Proleukin forward and ensure continued availability of this important medicine to patients and healthcare professionals.”

Greenhill & Co is serving as financial advisor and White & Case LLP as legal advisor to Clinigen.

– Ends –

Contact details

Clinigen Limited+44 (0)7957 984570
Michelle Shearly, Director of Communicationsmichelle.shearly@clinigengroup.com
Consilium Strategic Communications

Mary-Jane Elliott / Matthew Cole / Jessica Hodgson


Tel: +44 (0) 20 3709 5700Clinigen@consilium-comms.com

Notes to Editors

About Clinigen

Clinigen is a global, specialist pharmaceutical services company focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group supports pharmaceutical and biotech companies across the medical product lifecycle, from clinical through to commercial and operates from sites in North America, Europe, Africa and the Asia Pacific. Clinigen has more than 1,000 employees across five continents in 15 countries, and provides access in more than 120 countries every year.

For more information on Clinigen, please visit http://www.clinigengroup.com

About Proleukin

Proleukin (Aldesleukin is a recombinant interleukin-2 (IL-2), a cytokine whose role in the immune system has been extensively studied. At conventional doses it is used in the treatment of kidney cancer that has spread to another part of the body (metastatic kidney cancer). It is also currently being studied as part of adoptive cellular therapy. At significantly lower doses than those used in oncology aldesleukin has demonstrated immunomodulatory effects in certain auto-immune and inflammatory disease states by boosting the levels of a particular subset of white blood cells called T-regulatory lymphocytes (Tregs).

The Following Information is Intended for the U.S. Audience Only.

Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma (mRCC) and metastatic melanoma (mM).

Summary of Important Safety Information for Proleukin® (aldesleukin) for injection, for intravenous infusion.

WARNINGS

Therapy with Proleukin® (aldesleukin) should be restricted to patients with normal cardiac and pulmonary functions as defined by thallium stress testing and formal pulmonary function testing. Extreme caution should be used in patients with a normal thallium stress test and a normal pulmonary function test who have a history of cardiac or pulmonary disease.

Proleukin should be administered in a hospital setting under the supervision of a qualified physician experienced in the use of anticancer agents. An intensive care facility and specialists skilled in cardiopulmonary or intensive care medicine must be available.

Proleukin administration has been associated with capillary leak syndrome (CLS) which is characterized by a loss of vascular tone and extravasation of plasma proteins and fluid into the extravascular space. CLS results in hypotension and reduced organ perfusion which may be severe and can result in death. CLS may be associated with cardiac arrhythmias (supraventricular and ventricular), angina, myocardial infarction, respiratory insufficiency requiring intubation, gastrointestinal bleeding or infarction, renal insufficiency, edema, and mental status changes.

Proleukin treatment is associated with impaired neutrophil function (reduced chemotaxis) and with an increased risk of disseminated infection, including sepsis and bacterial endocarditis. Consequently, preexisting bacterial infections should be adequately treated prior to initiation of Proleukin therapy. Patients with indwelling central lines are particularly at risk for infection with gram positive microorganisms. Antibiotic prophylaxis with oxacillin, nafcillin, ciprofloxacin, or vancomycin has been associated with a reduced incidence of staphylococcal infections.

Proleukin administration should be withheld in patients developing moderate to severe lethargy or somnolence; continued administration may result in coma.

INDICATIONS AND USAGE

Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma (metastatic RCC).

Proleukin is indicated for the treatment of adults with metastatic melanoma.

Careful patient selection is mandatory prior to the administration of Proleukin.

Evaluation of clinical studies to date reveals that patients with more favorable ECOG performance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with a higher response rate and lower toxicity. Therefore, selection of patients for treatment should include assessment of performance status.

Experience in patients with ECOG PS > 1 is extremely limited.

CONTRAINDICATIONS

Proleukin® (aldesleukin) is contraindicated in patients with a known history of hypersensitivity to interleukin-2 or any component of the Proleukin formulation.

Proleukin is contraindicated in patients with an abnormal thallium stress test or abnormal pulmonary function tests and those with organ allografts. Retreatment with Proleukin is contraindicated in patients who have experienced the following drug-related toxicities while receiving an earlier course of therapy: sustained ventricular tachycardia (≥ 5 beats), cardiac arrhythmias not controlled or unresponsive to management, chest pain with ECG changes, consistent with angina or myocardial infarction, cardiac tamponade, intubation for > 72 hours, renal failure requiring dialysis > 72 hours, coma or toxic psychosis lasting > 48 hours, repetitive or difficult to control seizures, bowel ischemia/perforation, GI bleeding requiring surgery.

WARNINGS

Because of the severe adverse events which generally accompany Proleukin therapy at the recommended dosages, a thorough clinical evaluation should be performed to identify patients with significant heart, lung, kidney, liver or central nervous system impairment in whom Proleukin is not indicated for use. Patients with normal heart, lung, liver and central nervous system function may experience serious, life-threatening or fatal adverse events.

Should adverse events, requiring dose modification occur, dosage should be withheld rather than reduced.

Proleukin has been associated with exacerbation of preexisting autoimmune disease and inflammatory disorders. In some cases, the onset of new autoimmune diseases, such as vitiligo, may occur. Symptomatic hyperglycemia and/or diabetes mellitus have been reported during Proleukin therapy.

All patients should have thorough evaluation and treatment of CNS metastases and have a negative scan prior to receiving Proleukin therapy. New neurologic signs, symptoms, and anatomic lesions following Proleukin therapy have been reported in patients without evidence of CNS metastases. Neurologic signs and symptoms associated with Proleukin therapy usually improve after discontinuation of Proleukin therapy; however, there are reports of permanent neurologic defects. In patients with known seizure disorders, extreme caution should be exercised as Proleukin may cause seizures.

PRECAUTIONS

Patients should have normal cardiac, pulmonary, hepatic, and CNS function at the start of therapy. Capillary leak syndrome (CLS) begins immediately after Proleukin® (aldesleukin) treatment starts and is marked by increased capillary permeability to protein and fluids and reduced vascular tone.

Proleukin® (aldesleukin) treatment should be withheld for failure to maintain organ perfusion as demonstrated by altered mental status, reduced urine output, a fall in the systolic blood pressure below 90 mm Hg or onset of cardiac arrhythmias.

Recovery from CLS begins soon after cessation of Proleukin therapy. Usually, within a few hours, the blood pressure rises, organ perfusion is restored and reabsorption of extravasated fluid and protein begins.

Kidney and liver function are impaired during Proleukin treatment. Use of concomitant nephrotoxic or hepatotoxic medications may further increase toxicity to the kidney or liver.

Mental status changes including irritability, confusion, or depression which occur while receiving Proleukin may be due to bacteremia or early bacterial sepsis, hypoperfusion, occult CNS malignancy, or direct Proleukin-induced CNS toxicity. Patients should be evaluated for these and other causes of mental status changes. Alterations in mental status due solely to Proleukin therapy may progress for several days before recovery begins. Rarely, patients have sustained permanent neurologic deficits.

Proleukin enhancement of cellular immune function may increase the risk of allograft rejection in transplant patients.

Serious manifestations of eosinophilia involving eosinophilic infiltration of cardiac and pulmonary tissues can occur following Proleukin.

ADVERSE REACTIONS

The rate of drug-related deaths in the 255 metastatic RCC patients who received single-agent Proleukin® (aldesleukin) was 4% (11/255); the rate of drug-related deaths in the 270 metastatic melanoma patients who received single-agent Proleukin was 2% (6/270).

Adverse events are frequent, often serious, and sometimes fatal. The following adverse events (Grades 1-4) were seen in ≥ 30% of 525 patients (255 with metastatic kidney cancer and 270 with metastatic melanoma) treated with Proleukin: low blood pressure (71%), diarrhea (67%), low urine output (63%), chills (52%), vomiting (50%), shortness of breath (43%), rash (42%), increased bilirubin in blood (40%), decreased clotting of blood (37%), nausea (35%), confusion (34%), and decreased kidney function (33%).

Please see the full Prescribing Information, including Boxed Warning, for Proleukin® (aldesleukin) for injection, for intravenous infusion.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Golar to acquire New Fortress Energy’s stake in FLNG Hilli6.2.2023 14:21:46 CET | Press release

Golar LNG Limited (“Golar” or “the Company”) has agreed to acquire the New Fortress Energy Inc. (“NFE”) ownership stake in FLNG Hilli in exchange for Golar’s remaining 4.1 million shares in NFE and $100 million in cash. Golar will also take over approximately $323 million in debt obligations linked to Hilli. Pursuant to the transaction, Golar will acquire the 50% interest in Trains 1 and 2 of FLNG Hilli, currently owned by a subsidiary of NFE. Following closing of the transaction, Golar’s effective interest in currently contracted FLNG Hilli earnings will be as follows: 94.55% of Common Units that receive tolling related fees relating to trains 1 and 2, and 5% of Dutch Title Transfer Facility (“TTF”) related fees,89.1% of Series A units that receive Brent oil related fees,89.1% of Series B units that receive 95% of TTF related fees. Following the transaction Golar will have no remaining shareholding in NFE. Commenting on the transaction, Golar CEO Karl Fredrik Staubo said “Today’s anno

Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)6.2.2023 14:00:00 CET | Press release

BOSTON and LONDON, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the Company will present additional data from the open-label extension (OLE) of AP-0101, a Phase 2a study of SerpinPC, a novel inhibitor of activated protein C (APC) being developed for the treatment of hemophilia, during an oral presentation at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), on February 10, 2023. The Company recently announced positive results from the Phase 2a OLE at the 64th American Society of Hematology (ASH) Annual Meeting. “We are excited to share additional data from the OLE that further demonstrate the potential for SerpinPC to be a convenient subcutaneous treatment with a differentiated safety profile for people living with hemophilia,” said Saurabh Saha MD PhD, Chief Ex

Aktia’s Financial Statement Release 2023 will be published on Friday 17 February 2023 at 8.00 a.m.6.2.2023 14:00:00 CET | Press release

Aktia Bank Plc Press release 6 February 2023 at 03.00 p.m. Aktia’sFinancial Statement Release 2023 will be published on Friday17 February 2023 at 8.00 a.m. Aktia’s Financial Statement Release 2022 will be published on Friday 17 February 2023 at 8.00 a.m. (EET). The Financial Statement Release is available at Aktia’s website www.aktia.com after the publication. Webcast from the results event A live webcast will be sent from Aktia’s results event on Friday 17 February 2023 at 10.30 a.m. CEO Mikko Ayub and CFO Outi Henriksson will be presenting the results. The event will be held in English and can be seen live as a webcast or as a recording after the event at https://aktia.videosync.fi/2022-q4-results. The presentation material in English is available at Aktia’s website www.aktia.com before the results event. Aktia Bank Plc Further information: Lotta Borgström, Director, Investor Relations and Communications, tel. +358 10 247 6838, lotta.borgstrom@aktia.fi Distribution: Nasdaq Helsinki L

Aktias bokslutskommuniké för år 2022 publiceras fredagen 17.2.2023 kl. 8.006.2.2023 14:00:00 CET | Pressemelding

Aktia Bank Abp Pressmeddelande 6.2.2023 kl. 15.00 Aktias bokslutskommuniké för år 2022 publiceras fredagen 17.2.2023 kl. 8.00 Aktias bokslutskommuniké för år 2022 publiceras fredagen 17.2.2023 kl. 8.00. Bokslutskommunikén finns tillgänglig på Aktias webbplats på adressen www.aktia.com efter publiceringen. Webcast-sändning från resultattillställningen En direkt webcast-sändning arrangeras från Aktias resultattillställning fredagen 17.2.2023 kl. 10.30. Verkställande direktör Mikko Ayub och ekonomi- och finansdirektör Outi Henriksson presenterar resultatet. Tillställningen hålls på engelska och kan ses som en direkt webcast-sändning eller en inspelning efter tillställningen på adressen https://aktia.videosync.fi/2022-q4-results. Presentationsmaterialet på engelska finns tillgängligt på Aktias webbplats www.aktia.com före resultattillställningen. Aktia Bank Abp Mera information: Lotta Borgström, direktör för investerarrelationer och kommunikation, tfn 010 247 6838, lotta.borgstrom@aktia.fi

Bombardier CEO Éric Martel Evolves Leadership Team Structure as Part of Forward-Looking Growth Strategy, Building on Company Momentum6.2.2023 13:58:00 CET | Press release

Jean-Christophe Gallagher appointed Executive Vice President, Aircraft Sales and Bombardier Defense Paul Sislian appointed Executive Vice President of Bombardier Aftermarket Services & StrategyDavid Murray appointed Executive Vice President, Manufacturing, IT and Bombardier Operational Excellence SystemEric Filion joins Bombardier to the newly created role of Executive Vice President, Programs and Supply ChainMichel Ouellette will lead Engineering and Product Development until planned retirement later in 2023, following a 33-year, successful career MONTREAL, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Bombardier today announced a leadership team evolution that will focus on carrying forward the company’s positive momentum toward executing long-term growth and optimization strategies in the key areas of defense, services, continuous product improvement and next-generation manufacturing practices. “Bombardier has successfully embarked on its journey as a company focused on its world-class business